Philippe Legenne - Novartis Pharma AG

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 24 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

The DARPin Antiviral Ensovibep for Non-Hospitalized Patients with COVID-19: Results from EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study

Jeff Kingsley,Nagalingeswaran Kumarasamy, Luis Abrishamian,Marc Bonten,Awawu Igbinadolor, Martha Mekebeb-Reuter, Jennifer Rosa,Damodaran Solai Elango, Patricia Lopez,Pierre Fustier,Susana Goncalves,Charles G Knutson,Petra Kukkaro,Philippe Legenne,Krishnan Ramanathan, Shantha Rao,Evgeniya Reshetnyak,Vaia Stavropoulou,Nina Stojcheva,Michael T Stumpp,Andreas Tietz,Marianne Soergel, Richa Chandra

Open Forum Infectious Diseases (2024)

引用0浏览0引用

The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients with Coronavirus Disease 2019: Results from EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study

Jeff Kingsley,Nagalingeswaran Kumarasamy, Luis Abrishamian,Marc Bonten,Awawu Igbinadolor, Martha Mekebeb-Reuter, Jennifer Rosa,Damodaran Solai Elango, Patricia Lopez,Pierre Fustier,Susana Goncalves,Charles G. Knutson,Petra Kukkaro,Philippe Legenne,Krishnan Ramanathan, Shantha Rao,Evgeniya Reshetnyak,Vaia Stavropoulou,Nina Stojcheva,Michael T. Stumpp,Andreas Tietz,Marianne Soergel, Richa Chandra

OPEN FORUM INFECTIOUS DISEASESno. 6 (2024)

引用0浏览0WOS引用

A Phase 1b/2 Study Evaluating Efficacy and Safety of MP0250, a Designed Ankyrin Repeat Protein (darpin) Simultaneously Targeting Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF), in Combination with Bortezomib and Dexamethasone, in Patients with Relapsed or Refractory Multiple Myeloma

Stefan Knop,Monika Szarejko,Norbert Grzasko,Sara Bringhen,Karolin Trautmann-Grill,Artur Jurczyszyn,Angelo Vacca,Cyrus Khandanpour,Barbara Gamberi,Ludek Pour,Katrine F. Iversen,Michael T. Stumpp, Cosima Suter,Keith M. Dawson,Christof Zitt,Philippe Legenne,Vaia Stavropoulou, Martin F. Fey,Nicolas Leupin,Hartmut Goldschmidt

EJHaemno. 5 (2024): 940-950

引用0浏览0WOS引用

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Thomas Pabst,Mojca Jongen‐Lavrencic,Steffen Boettcher,G. Hüls,David C. de Leeuw,Philippe Legenne,Mariola Dymkowska, Christiane Andrieu,Oliver Schönborn‐Kellenberger,Paul Baverel,Zita Arany,Elena Fernández,Anne Goubier,Vladimir Kirkin,Nicolas Leupin, Marion Subklewe

Bloodno. Supplement 1 (2023): 2921-2921

引用0浏览0引用

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Thomas Pabst,Mojca Jongen-Lavrencic,Steffen Boettcher,Geert A. Huls,David C. de Leeuw,Philippe Legenne,Mariola Dymkowska, Christiane Andrieu,Oliver Schoenborn-Kellenberger,Paul G. Baverel,Zita Arany,Elena Fernandez,Anne Goubier,Vladimir Kirkin,Nicolas Leupin,Marion Subklewe

Bloodno. Supplement 1 (2023): 2921-2921

引用0浏览0引用

Ensovibep, a SARS‐CoV‐2 Antiviral Designed Ankyrin Repeat Protein, is Safe and Well Tolerated in Healthy Volunteers: Results of a First‐in‐human, Ascending Single‐dose Phase 1 Study

Nina Stojcheva, Stacy Gladman,Marianne Soergel,Christof Zitt, Roxana Drake, Tony Lockett,Carine Marchand,Pierre Fustier,Vaia Stavropoulou,Elena Fernandez,Nathana Lopes Pettigiani, Kate Watkins,Adeep Puri, Randall Watson,Philippe Legenne,Michael T. Stumpp,Malcolm Boyce

BRITISH JOURNAL OF CLINICAL PHARMACOLOGYno. 7 (2023): 2295-2303

引用0浏览0WOS引用

Phase I Study of MP0317, a FAP-dependent DARPin, for Tumor-Localized CD40 Activation in Patients with Advanced Solid Tumors

Carlos A. Gomez-Roca,Neeltje Steeghs,Eelke Hiddo Gort, Hilde A. M. De Winter,Elena Fernandez,Vaia Stavropoulou,Nina Stojcheva,Paul Baverel,Jennifer Krieg,Kyriaki Ioannou,Ana Maria Florescu, Patrick Mossi,Lea Hoenig, Bruno Baud-Berthier,Vladimir Kirkin,Anne Goubier,Philippe Legenne,Philippe Alexandre Cassier

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

721 Ongoing Phase 1 Study of MP0317, a FAP-CD40 DARPin, Shows a Favorable Safety Profile and Early Evidence of Tumor-Localized CD40 Activation in Patients with Advanced Solid Tumors

Anne Goubier,Neeltje Steeghs,Carlos Gomez-Roca,Philippe Cassier,Elena Fernandez,Eelke Gort,Hilde De Winter,Vaia Stavropoulou,Nina Stojcheva,Paul Baverel,Jennifer Krieg,Kyriaki Ioannou,Ana Maria Florescu, Lea Hoenig, Bruno Baud-Berthier, Michael P Sanderson,Vladimir Kirkin,Philippe Legenne

Regular and Young Investigator Award Abstracts (2023)

引用0浏览0引用

1475 A Phase 1 Study to Characterize the Safety and Tolerability of MP0317, a Tumor Targeting FAP Dependent CD40 Agonist DARPin, in Patients with Relapsed/refractory Solid Tumors

Hilde De Winter,Elena Fernandez,Vaia Stavropoulou,Nina Stojcheva,Paul Baverel,Carlos Gomez-Roca,Eelke Gort,Neeltje Steeghs,Kyriaki Ioannou,Ana Maria Florescu,Jennifer Krieg, Patrick Mossi,Vladimir Kirkin,Philippe Legenne,Philippe Cassier

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022): A1534-A1534

引用0浏览0引用

A Case of Sustained Tumor Regression with MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Prior Trastuzumab and Pertuzumab

Stefanie Fischer, Thorsten O. Gotze,Aurelius Omlin,Richard D. Baird,Keith M. Dawson,Christof Zitt,Zita Arany,Gaby Tresch,Ulrike Fiedler,Simone Jeger,Samson Fung,Philippe Legenne,Nicolas Leupin,Andreas Schneeweiss,Carlo Fremd

JCO PRECISION ONCOLOGY（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn